Therapeutic | Pateclizumab |
Target | LTA |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK |
100% seqID Fv Structure | 4mxv [Fvs: FE, HL, YX], 4mxw [Fvs: HL, WV] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4mxv [Fvs: FE, HL, YX] |
100% seqID Structure | 4mxw [Fvs: HL, WV] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2011 |
INN Year Recommended | 2012 |
Companies Involved | Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Rheumatoid arthritis |
Notes |